German Pharma Giant Bayer Proposes $7.25 Billion Settlement Over Monsanto's Roundup Cancer Claims In US

Core Viewpoint - Bayer AG proposed a $7.25 billion settlement to resolve thousands of U.S. lawsuits claiming that its weedkiller Roundup causes cancer, originally made by Monsanto, which Bayer acquired in 2018 for over $60 billion [1] Group 1: Settlement Details - The proposed settlement aims to provide closure for Bayer, reducing litigation uncertainty and potential exposure from future Supreme Court rulings [2] - Monsanto will fund the settlement through capped annual payments over up to 21 years, totaling as much as $7.25 billion, and has agreed to settle additional Roundup cases under confidential terms [3] - The settlement proposal was filed in Missouri's St. Louis Circuit Court, where many lawsuits were initiated, claiming inadequate warnings about non-Hodgkin lymphoma risks associated with glyphosate [4] Group 2: Legal Context - The proposed settlement comes as the U.S. Supreme Court prepares to hear arguments regarding Bayer's assertion that EPA's approval of Roundup without a cancer warning should nullify state court claims, and the settlement will not impact this case [5] - Bayer's Monsanto unit secured a significant legal victory when a Washington state appeals court overturned a $185 million verdict against the company related to chemical contamination [6] - The Trump administration backed Bayer in its Roundup cases, urging the Supreme Court to limit state-law claims, which could provide regulatory clarity for farmers [7]